According to the Synergy Research Group report, the most active CROs in the region were OCT, Quintiles, PSI, Synergy Research Group and IPHARMA. It should be noted that OCT has been working with the largest number of patients during this period. AbbVie Inc. stands first in the list of the most active foreign pharmaceutical companies in terms of initiated clinical trials in Q3, while BIOCAD and Severnaya Zvezda were named the most active among Russian companies.
In 2016, OCT obtained approvals for 12 new clinical trials and became one of the leading CROs in the region (not counting other trials where sponsors independently prepared regulatory submissions).
To date, OCT has successfully completed more than
250 clinical projects.